SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Paul Robeson

PatientPaul Robeson
Date of birth1967-04-09
IdentifiersMRN HR-ML048-SYN; SSN (made up) 000-48-2647
Document date2026-04-20
AuthorTheodore Bankole-Ashworth, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week review of depression treatment. [S]

History of Present Illness

Mr. Robeson returns six weeks after starting sertraline. He took 50 mg for two weeks with mild nausea that passed in a week, and after the nurse's phone check he has taken 100 mg for three and a half weeks. He has been to five behavioral activation sessions and has begun short walks and an hour of reading each day, but he still wakes early, has little pleasure, and has not sung. He has had no thoughts of being better off dead for three weeks. He has noticed no rise in energy or reduced need for sleep. He takes every dose and keeps his medicines locked. [S]

ElementDetail
MedicinesSertraline 50 mg for two weeks, then 100 mg for three and a half weeks; every dose taken
TherapyFive behavioral activation sessions
MoodPHQ-9 19 from 22; no thoughts of death for three weeks
Side effectsNausea in the first week only

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; appetite a little better; weight 99.5 kg
PsychiatricPositiveLow mood and little pleasure; early waking; no thoughts of suicide; no elation
GastrointestinalNegativeNausea gone
NeurologicalNegativeNo tremor or headache

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 50 mg tablet, one tablet each morning50 mg each morning for two weeksOral route2026-03-12 to 2026-03-25completedS
Sertraline 100 mg tablet, one tablet each morning100 mg each morningOral route2026-03-26 to 2026-04-19completedS
Sertraline 50 mg tablets, three tablets (150 mg) each morning150 mg each morning for two weeksOral route2026-04-20 to 2026-05-03completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-20Body height190cmS
2026-04-20Body weight99.5kgS
2026-04-20Body mass index (BMI) [Ratio]27.6kg/m2S
2026-04-20Systolic blood pressure126mm[Hg]S
2026-04-20Diastolic blood pressure78mm[Hg]S
2026-04-20Heart rate72/minS
2026-04-20Respiratory rate14/minS
2026-04-20Body temperature36.7CelS
2026-04-20Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-20Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-04-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]19{score}S

Physical Exam

Vital signs recorded on 2026-04-20; see the Vital Signs section. [S]

SystemFinding
GeneralWeight 99.5 kg; blood pressure 126/78, pulse 72
PsychiatricSlowed; constricted affect, a little brighter; logical; no thoughts of suicide

Problems

ProblemClinical statusVerificationCodeProvenance
About three months of low mood, exhaustion, poor sleep with waking at three in the morning, loss of interest in singing and reading, poor appetite with 5 kg weight loss, and withdrawal from friends, in a man of 58 under sustained political pressure; PHQ-9 22 with thoughts of being better off dead; depression suspected; medical causes being excluded and urgent psychiatric consultation arrangedresolvedconfirmed R53.83S — Synthetic presenting problem at intake, superseded by the diagnosis at the psychiatric consultation; anchored to his documented depression and loss of work (D).
Major depressive disorder, recurrent, severe, without psychotic features (second episode; structured diagnostic interview; MDQ negative and no past hypomanic or manic episode on interview)activeconfirmed F33.2S — Synthetic modern diagnosis anchored to his documented depression after the 1955 breakdown (D); the bipolar interpretation (R) is addressed and not adopted.
Sustained political persecution: passport withheld, concerts and recordings cancelled, income lost, and surveillance by federal agencies; a major and realistic stressor, not a delusionactiveconfirmed Z60.5S — Synthetic coding of his documented persecution as a social determinant of his depression.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPHQ-9Baseline and at least monthly during acute treatment (CMID)Completed today19, down 14 percent from 22; item 9 scored 0
SurveyPHQ-9 between visits, rated by the psychologist at each sessionAt each therapy sessionDeferredMissed: no PHQ-9 was collected about four weeks into treatment; the two-week nurse call checked side effects and safety but not the PHQ-9, and no visit was booked at four weeks. No harm judging by today's score and his safety review. Corrective action: the psychologist now rates the PHQ-9 at each weekly session and reports any rise or positive item 9 the same day
SurveySuicide-risk review (C-SSRS screen since the last visit), safety plan, locked medicines and the 988 Suicide & Crisis LifelineEvery visit during active treatmentCompleted todayNo thoughts of suicide for three weeks; medicines locked; safety plan reviewed
LaboratorySodium (SSRI or SNRI in an older adult)Baseline, about four to six weeks after starting, and with symptomsCompleted today138 mmol/L, normal
Medication safetyAdherence and adverse-effect reviewEvery visitCompleted todayEvery dose taken; nausea in the first week only
Medication safetyAdequacy of the antidepressant trial (dose and duration)At each review: at least four to eight weeks at an adequate dose before judging responseCompleted todayThree and a half weeks at 100 mg: not yet an adequate trial; dose raised
Medication safetyWatch for hypomania or mixed features after starting or changing an antidepressantEvery visit; repeat the MDQ if features emergeCompleted todayNo elation, reduced need for sleep or racing thoughts
ReferralBehavioral activation with a psychologistWeekly for about sixteen sessionsCompleted todayFive sessions attended; daily walks and reading scheduled
Self-managementTrust, confidentiality and culturally responsive careEvery visitCompleted todayHe feels able to speak freely with his therapist
ReferralSocial work for income and costsMonthlyCompleted todayMeeting the social worker monthly about costs

Goal progress:

Guideline basis: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Williams DR, et al. Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Arch Gen Psychiatry 2007;64(3):305-315 (2007)

Follow-up: Sertraline 200 mg in two weeks. Review in seven weeks with the PHQ-9 and sodium. Weekly behavioral activation with a PHQ-9 at each session. Call or text 988 at any time in a crisis. Next scheduled visit 2026-06-08: three-month review: no response to an adequate sertraline trial; switch to venlafaxine. [S]